Ponvory (ponesimod) has been approved for use on the NHS in Scotland by the Scottish Medicines Consortium (SMC) for relapsing remitting multiple sclerosis (MS).
Ponvory is taken daily in tablet form and has been demonstrated to reduce relapse rates. It alters the behaviour of immune cells to stop them invading the brain and causing damage. It belongs to the same class of drugs as Gilenva (fingolimod).
This decision comes just weeks after the National Institute for Health and Care Excellence (NICE) did not recommend Ponvory as a treatment on the NHS in England and Wales, although this is back under review, with the final decision expected later this year.
The news will be welcomed by many people with MS in Scotland as it offers more choice, especially for those who would rather take a tablet than an injection.
Source: MS-UK 11 November